Basic research of adjuvant chemotherapy for locally invasive bladder cancer

本研究旨在建立具有临床实用价值的浸润性膀胱癌多学科治疗方法。自1992年以来，我们观察了CPM+THP-ADM+CDDP(CAP)、MTX+VLB+THP-ADM+CDDP(M-VAC)和MTX+Epi-ADM+CDDP(MEC)联合化疗方案对N-丁基-N-(4-羟基丁基)亚硝胺(BBN)诱发小鼠膀胱癌的影响。这些实验包括两个目的：1)对膀胱癌发生发展的影响(实验1)，2)对膀胱癌的影响，抗肿瘤作用(实验2)。在实验1中，0.05%BBN治疗12周后，动物每3周接受3个周期的CAP或每4周接受3个周期的M-VAC或MEC。另一方面，在实验2中，动物在0.5%BBN治疗12周和16周不治疗后，以与实验1相同的方式接受每种方案。在实验1中，化疗组的肿瘤发生率显著低于单纯BBN组。然而，在实验2中，每两组之间没有显著差异。因此，CAP、M-VAC和MEC对小鼠膀胱癌的生长有抑制作用。提示CAP、M-VAC和MEC方案是浸润性膀胱癌辅助化疗的有效方案。

The present investigation was conducted to establish clinically useful multidisciplinary treatment for invasive bladder cancer. Since 1992, we examined the effects of combination chemotherapeutic regiments, CPM+THP-ADM+CDDP (CAP), MTX+VLB+THP-ADM+CDDP (M-VAC) and MTX+Epi-ADM+CDDP (MEC) on the urinary bladder carcinogenesis induced by N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN) in mice. Those experiments include two objectives to examine ; 1) the effects on the development of bladder carcinoma (Exp.1), and 2) the effects on the bladder carcinoma, anti-tumor effects (Exp.2). In Exp.1, animals received 3 cycles of CAP every 3 weeks or 3 cycles of M-VAC or MEC every 4 weeks after 0.05% BBN treatment for 12 weeks. On the other hand, In Exp.2, animals received each regimen with same manner as Exp.1 after 0.5% BBN treatment for 12 weeks and no treatment for 16 weeks. In Exp.1, tumor incidences of chemotherapy groups were significantly lower than that of BBN alone group. However, in Exp.2, significant difference was not observed between every two groups. Therefore, inhibitory effects of CAP,M-VAC and MEC on the development of mouse bladder carcinoma were seen. These results suggested that CAP,M-VAC and MEC were useful regimens for adjuvant chemotherapy for invasive bladder cancer.